Alliance Researchers Identify Genetic Variants Linked to Drug-Induced Hypertension From Bevacizumab -- Results Offer Pathway to Preventive Patient Screening

Results from the largest study of its kind led researchers from the Alliance for Clinical Trials in Oncology to identify a genetic variant that can be used to predict if patients with cancer will develop hypertension from the cancer drug bevacizumab. Federico Innocenti, MD, PhD, Associate Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, presented findings from this unique study at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer


UPCOMING MEETINGS

2021 Spring & Fall Group Meetings
- May 13-15 & November 4-6

All meetings are open to all
Alliance members
 

TWEETS

FROM THE NCI